StreetAlpha
13F holdings · Q3 2026

Birchview Capital

Burlington, VT · files as Birchview Capital, LP
Know the moment Birchview Capital filesYou follow Birchview Capital An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Holdings as of Sep 30, 2026Filed Nov 13, 2026Next filing due Feb 15, 2027CIK 1618205

Birchview Capital reported 79 stocks worth $173M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are KLAC (18.8%), BMY (8.1%) and LRCX (5.7%). Compared with Q2 2026, the fund opened new positions in RARE, CTNM and IRLA, added to SLDB, HALO and VIR, trimmed KLAC, BMY and LRCX and sold out of VERA, QURE and BIOA.

Latest filing: what Birchview Capital did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
23 new13 added20 trimmed16 sold outBought about $24.1M · sold about $33.8M
New 23
See all 23 →
Added 13
See all 13 →
Trimmed 20
See all 20 →
Sold out 16
See all 16 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$173M−19.0% vs last quarter
Stocks held7923 new · 16 sold out
Top 5 weight41.2%fairly concentrated
Turnover33%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
KLAC
Kla Corp
$32.5M18.8%167K−12K (−6%)6 of 8
2
BMY
Bristol Myers Squibb Co
$14M8.1%224K−73K (−25%)8 of 8
3
LRCX
Lam Research Corp
$9.9M5.7%30K−5,000 (−14%)4 of 8
4
BDSX
Biodesix Inc
$8.6M4.9%287KNo change8 of 8
5
CORT
Corcept Therapeutics Inc
$6.4M3.7%55K−2,000 (−3%)8 of 8
6
OVV
Ovintiv Inc
$6.2M3.6%108KNo change8 of 8
7
RARE
Ultragenyx Pharmaceutical in
$5.6M3.2%374KNew position7 of 8
8
SLDB
Solid Biosciences Inc
$5.2M3.0%716K+50K (+7%)7 of 8
9
PTGX
Protagonist Therapeutics Inc
$4.9M2.9%35KNo change8 of 8
10
PRTA
Prothena Corp PLC
$3.8M2.2%449KNo change8 of 8
🔒 69 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
VERA
Vera Therapeutics Inc
$2.5M58K
QURE
Uniqure NV
$2.3M51K
BIOA
Bioage Labs Inc
$1.7M69K
GPCR
Structure Therapeutics Inc
$1.3M24K
NVO
Novo-Nordisk A S F
$1.2M24K

🔒 Free account: see all 16.

Reported value

last 8 quarters
$246MQ4 '24
$115MQ1 '25
$101MQ2 '25
$132MQ3 '25
$171MQ4 '25
$176MQ1 '26
$214MQ2 '26
$173MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 13, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Birchview Capital 13F FAQ

What does Birchview Capital own?

Birchview Capital reported 79 stocks worth $173M in its 13F filing for Q3 2026, filed Nov 13, 2026. Its largest holdings are KLAC (18.8%), BMY (8.1%) and LRCX (5.7%). The table above lists every position in the filing (the top 10 without an account).

What did Birchview Capital buy and sell in Q3 2026?

Compared with Q2 2026: 23 new positions, 13 added to, 20 trimmed and 16 sold out. New positions include RARE, CTNM and IRLA. It sold all of VERA, QURE and BIOA.

When will Birchview Capital file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Birchview Capital's portfolio worth?

The Q3 2026 filing reports $173M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.